
Innovent and Eli Lilly Expand Partnership for Breast Cancer Drug in China
Innovent Biologics has secured the exclusive commercialization rights for Eli Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China, marking the eighth collaboration between the two pharmaceutical firms. Under the new agreement, Innovent will manage all local marketing and distribution while Lilly retains manufacturing and development responsibilities.























